Extensive Intra-tumor Heterogeneity in Primary Human Glial Tumors as a Result of Locus Non-specific Genomic Alterations

Genomic changes are a hallmark of the neoplastic process. These range from alterations at specific loci and defined karyotypic changes which influence tumor behavior to generalized alterations exemplified by microsatellite instability. Generalized genomic changes within a tumor would be evidence in favor of the mutator hypothesis which postulates a role for such extensive changes during tumorigenesis. In this report, we have used the DNA fingerprinting technique of randomly amplified polymorphic DNA (RAPD) analysis to study genomic alterations within primary human astrocytic tumors (gliomas) in a locus non-specific manner. The RAPD fingerprinting profile of consecutive segments of tumors 2 mm across was studied; 17 astrocytic (high- and low-grade) tumors were sectioned end to end. Tissue from 50 consecutive sections, 40 µm thick (total 2 mm across), was pooled and taken to be a tumor compartment. DNA was subjected to RAPD amplification by 15 random 10-mer primers.A tumor segment was taken to have a DNA fingerprinting pattern different from others in the same specimen when its RAPD profile differed from others by at least one band of one RAPD reaction. All but one of the tumors showed compartments with a unique genetic profile, indicating genomic instability leading to widespread intra-tumor genetic heterogeneity. Eight tumors were also studied for loss of heterozygosity (LOH) of the p53 and D17S379 loci in the different segments as examples of alteration of specific tumor influencing loci. Three showed LOH of p53, which was limited to only one compartment of each tumor.The extensive intra-tumor genetic instability detected in this study is suggestive of the overall high rate of change in the genomes of tumors including those of a lower grade. It is hypothesized that some of these altered clones, which manifest as zones of heterogeneity in a solid tumor, may accumulate changes at loci known to influence tumor behavior, and thus clinical outcome.

[1]  S. Coons,et al.  Regional heterogeneity in the DNA content of human gliomas , 1993, Cancer.

[2]  G. Heppner.  Tumor heterogeneity. , 1984, Cancer research.

[3]  W. Shapiro,et al.  BCNU-sensitivity in parental cells and clones from four freshly resected near-diploid human gliomas: An astrocytoma, an anaplastic astrocytoma and two glioblastomas multiforme , 1993, Journal of Neuro-Oncology.

[4]  S. Wright,et al.  The shifting balance theory and macroevolution. , 1982, Annual review of genetics.

[5]  A. Velázquez,et al.  Isolation and characterization of allelic losses and gains in colorectal tumors by arbitrarily primed polymerase chain reaction. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[6]  W. Shapiro,et al.  Isolation, karyotype, and clonal growth of heterogeneous subpopulations of human malignant gliomas. , 1981, Cancer research.

[7]  J. Ellis,et al.  Heteroduplex molecules formed between allelic sequences cause nonparental RAPD bands. , 1994, Nucleic acids research.

[8]  G. Capellá,et al.  Assessment of genomic damage in colorectal cancer by DNA fingerprinting: prognostic applications. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Coons,et al.  Regional Heterogeneity in the Proliferative Activity of Human Gliomas as Measured by the Ki‐67 Labeling Index , 1993, Journal of neuropathology and experimental neurology.

[10]  Han Mk,et al.  Genetic analysis using random amplified polymorphic DNA markers. , 1993 .

[11]  R. Humphrey,et al.  Differential response by human melanoma cells to 1,3-bis-(2-chloroethyl)-1-nitrosourea and bleomycin. , 1973, Mutation research.

[12]  J. Hallervorden.  [Tumors of the nervous system]. , 1951, Strahlentherapie.

[13]  D. Dexter,et al.  Clinical and pharmacological implications of cancer cell differentiation and heterogeneity. , 1979, Biochemical pharmacology.

[14]  I. Fidler,et al.  Biological and experimental consequences of the zonal composition of solid tumors. , 1981, Cancer research.

[15]  A. Jeffreys,et al.  Detection of somatic changes in human cancer DNA by DNA fingerprint analysis. , 1987, British Journal of Cancer.

[16]  C. Daumas-Duport,et al.  Postoperative radiotherapy of supratentorial low-grade gliomas. , 1989, International journal of radiation oncology, biology, physics.

[17]  G. Caetano-Anollés,et al.  DNA Amplification Fingerprinting Using Very Short Arbitrary Oligonucleotide Primers , 1991, Bio/Technology.

[18]  W. Whong,et al.  Detection of genomic instability in lung cancer tissues by random amplified polymorphic DNA analysis. , 1998, Carcinogenesis.

[19]  J. Moringlane,et al.  Evidence of focal genetic microheterogeneity in glioblastoma multiforme by area-specific CGH on microdissected tumor cells. , 1999, Journal of neuropathology and experimental neurology.

[20]  D. Tarin,et al.  DNA fingerprinting survey of various human tumors and their metastases. , 1992, Cancer research.

[21]  R Carrozzo,et al.  Dinucleotide repeat polymorphism mapping to the critical region for lissencephaly (17p13.3). , 1993, Human molecular genetics.

[22]  S. Baylin,et al.  p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3 , 1995, Nature Genetics.

[23]  P. Edwards.  Heterogeneous expression of cell-surface antigens in normal epithelia and their tumours, revealed by monoclonal antibodies. , 1985, British Journal of Cancer.

[24]  W. Paulus,et al.  Intratumoral histologic heterogeneity of gliomas. A quantitative study , 1989, Cancer.

[25]  J. Serth,et al.  Polymerase chain reaction detection of a highly polymorphic VNTR segment in intron 1 of the human p53 gene. , 1993, Clinical chemistry.

[26]  J. Williams,et al.  Genetic analysis using random amplified polymorphic DNA markers. , 1993, Methods in enzymology.

[27]  F. Miller,et al.  Growth interaction in vivo between tumor subpopulations derived from a single mouse mammary tumor. , 1980, Cancer research.

[28]  S. Goldman,et al.  Regional glucose metabolism and histopathology of gliomas: A study based on positron emission tomography‐guided stereotactic biopsy , 1996, Cancer.

[29]  C. Marshall,et al.  γ-Glutamyltranspeptidase and the ras-induced Transformation of a Rat Liver Cell Line , 1986 .

[30]  S. Coons,et al.  Cytogenetic and flow cytometry DNA analysis of regional heterogeneity in a low grade human glioma. , 1995, Cancer research.

[31]  M. Micheli,et al.  Randomly amplified polymorphic DNA fingerprinting using combinations of oligonucleotide primers. , 1993, BioTechniques.

[32]  C. Daumas-Duport,et al.  Oligodendrogliomas. Part I: Patterns of growth, histological diagnosis, clinical and imaging correlations: A study of 153 cases , 1997, Journal of Neuro-Oncology.

[33]  F. Mitelman,et al.  The chromosomes of fifty primary Rous rat sarcomas. , 2009, Hereditas.

[34]  C. Sarkar,et al.  Loss of heterozygosity of a locus on 17p13.3, independent of p53, is associated with higher grades of astrocytic tumours , 1997, Oncogene.

[35]  M. Pillay,et al.  Anomalies in direct pair-wise comparisons of RAPD fragments for genetic analysis. , 1995, BioTechniques.

[36]  G. Reifenberger,et al.  Immunohistochemical determination of protein kinase C expression and proliferative activity in human brain tumors , 2004, Acta Neuropathologica.

[37]  R. Shatters,et al.  Effect of transition interval between melting and annealing temperatures on RAPD analyses. , 1995, BioTechniques.

[38]  Jing Yin,et al.  Loss of heterozygosity of p53 in oral cancers demonstrated by the polymerase chain reaction , 1993, Cancer.

[39]  T. Mikkelsen,et al.  Clonal expansion of p53 mutant cells is associated with brain tumour progression , 1992, Nature.

[40]  D. Dexter,et al.  Heterogeneity of tumor cells from a single mouse mammary tumor. , 1978, Cancer research.

[41]  C. Sarkar,et al.  Genetic alterations in brain tumors identified by RAPD analysis. , 1998, Gene.

[42]  G. Neal,et al.  Monoclonal antibody against tumour‐derived cell line shows heterogeneity of altered hepatocytes during afb1‐induced carcinogenesis , 1984, International journal of cancer.

[43]  M. Hamou,et al.  Cellular and tumoural heterogeneity of EGFR gene amplification in human malignant gliomas , 2005, Acta Neurochirurgica.

[44]  F. Mitelman,et al.  Tumor Etiology and Chromosome Pattern , 1972, Science.

[45]  D. Ellsworth,et al.  Artifactual variation in randomly amplified polymorphic DNA banding patterns. , 1993, BioTechniques.

[46]  Thomas Boehm,et al.  Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance , 1997, Nature.